<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BR</journal-id>
<journal-title-group>
<journal-title>Biomedical Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">2049-9434</issn>
<issn pub-type="epub">2049-9442</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/br.2016.639</article-id>
<article-id pub-id-type="publisher-id">BR-0-0-639</article-id>
<article-categories>
<subj-group>
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>GUO</surname><given-names>ZHENGRONG</given-names></name>
<xref rid="af1-br-0-0-639" ref-type="aff">1</xref>
<xref rid="af2-br-0-0-639" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>PENG</surname><given-names>HUANYAN</given-names></name>
<xref rid="af1-br-0-0-639" ref-type="aff">1</xref>
<xref rid="af3-br-0-0-639" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>KANG</surname><given-names>JIWEN</given-names></name>
<xref rid="af1-br-0-0-639" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>SUN</surname><given-names>DIANXING</given-names></name>
<xref rid="af1-br-0-0-639" ref-type="aff">1</xref>
<xref rid="c1-br-0-0-639" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-br-0-0-639"><label>1</label>The Liver Diseases Diagnosis and Treatment Center of PLA, Bethune International Peace Hospital, Shijiazhuang, Hebei 050082, P.R. China</aff>
<aff id="af2-br-0-0-639"><label>2</label>Department of Gastroenterology, The First Hospital of Shijiazhuang City, Shijiazhuang, Hebei 050011, P.R. China</aff>
<aff id="af3-br-0-0-639"><label>3</label>Hebei Medical University Graduate School, Shijiazhuang, Hebei 050017, P.R. China</aff>
<author-notes>
<corresp id="c1-br-0-0-639"><italic>Correspondence to</italic>: Professor Dianxing Sun, The Liver Diseases Diagnosis and Treatment Center of PLA, Bethune International Peace Hospital, 398 West Zhongshan Road, Shijiazhuang, Hebei 050082, P.R. China, E-mail: <email>sundianxing@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>05</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>03</month>
<year>2016</year></pub-date>
<volume>4</volume>
<issue>5</issue>
<fpage>528</fpage>
<lpage>534</lpage>
<history>
<date date-type="received"><day>23</day><month>12</month><year>2015</year></date>
<date date-type="accepted"><day>09</day><month>03</month><year>2016</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2016, Spandidos Publications</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<abstract>
<p>Cell-penetrating peptides (CPPs), also known as protein transduction domains, are a class of diverse peptides with 5&#x2013;30 amino acids. CPPs are divided into cationic, amphipathic and hydrophobic CPPs. They are able to carry small molecules, plasmid DNA, small interfering RNA, proteins, viruses, imaging agents and other various nanoparticles across the cellular membrane, resulting in internalization of the intact cargos. However, the mechanisms of CPP internalization remain to be elucidated. Recently, CPPs have received considerable attention due to their high transduction efficiency and low cytotoxicity. These peptides have a significant potential for diagnostic and therapeutic applications, such as delivery of fluorescent or radioactive compounds for imaging, delivery of peptides and proteins for therapeutic application, and delivery of molecules into induced pluripotent stem cells for directing differentiation. The present study reviews the classifications and transduction mechanisms of CPPs, as well as their potential applications.</p>
</abstract>
<kwd-group>
<kwd>cell-penetrating peptides</kwd>
<kwd>protein transduction domain</kwd>
<kwd>peptide therapeutic</kwd>
<kwd>internalization</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<label>1.</label>
<title>Introduction</title>
<p>The cellular membrane is an effective semi-permeable barrier that is essential for cell survival and function. However, it is also a major obstacle for intracellular delivery of cargos for diagnosis and treatment of human diseases. Small molecules enter cells through specific carriers and channels in the membrane. However, macromolecules are generally unable to use these modes of entry into cells. Thus, it is important to develop tools to facilitate cellular uptake of large molecules for basic research and biomedical applications.</p>
<p>Cell-penetrating peptides (CPPs) are a promising class of short peptides with the ability to translocate across the cell membrane (<xref rid="b1-br-0-0-639" ref-type="bibr">1</xref>). CPPs generally contain 5&#x2013;30 amino acids. In 1988, two independent groups reported transactivator of transcription (Tat) protein of the human immunodeficiency virus (HIV) as the first CPP. Tat has the ability to enter cultured mammalian cells and promote viral gene expression (<xref rid="b2-br-0-0-639" ref-type="bibr">2</xref>,<xref rid="b3-br-0-0-639" ref-type="bibr">3</xref>). Subsequently, several polycationic CPPs have been identified. For example, Antp, the third helix of the homeotic protein of <italic>Drosophila melanogaster</italic> Antennapedia, can enter nerve cells and regulate neural morphogenesis (<xref rid="b4-br-0-0-639" ref-type="bibr">4</xref>), and vp22, the herpes virus structural protein, has potential in protein delivery (<xref rid="b5-br-0-0-639" ref-type="bibr">5</xref>). CPPs can act as carriers as they have the ability to deliver macromolecular cargos, such as polypeptides (<xref rid="b6-br-0-0-639" ref-type="bibr">6</xref>), nanoparticles (<xref rid="b7-br-0-0-639" ref-type="bibr">7</xref>) and oligonucleotides (<xref rid="b8-br-0-0-639" ref-type="bibr">8</xref>) into cells. However, the mechanisms of CPP internalization are mostly unknown. The possible mechanisms are direct penetration, endocytosis and translocation through the formation of a transitory structure. The present review provides a broad overview of the classification, mechanisms of transduction and potential applications of CPPs.</p>
</sec>
<sec>
<label>2.</label>
<title>Classification of cell-penetrating peptides</title>
<sec>
<title/>
<sec>
<title>General</title>
<p>The classification of CPPs varies based on their physicochemical properties. In general, CPPs can be divided into three classes: Cationic, amphipathic and hydrophobic (<xref rid="tI-br-0-0-639" ref-type="table">Table I</xref>) (<xref rid="b9-br-0-0-639" ref-type="bibr">9</xref>). Currently, &#x003E;100 different CPPs have been reported and patented. More than 83&#x0025; of CPPs, which includes Tat, the first identified CPP, have a net-positive charge. Amphipathic CPPs, which comprise cationic and anionic peptides, are 44&#x0025; of CPPS, while only 15&#x0025; of CPPs are hydrophobic (<xref rid="b10-br-0-0-639" ref-type="bibr">10</xref>).</p>
</sec>
<sec>
<title>Cationic CPPs</title>
<p>Cationic peptides are a class of peptides that contain a high positive charge. The first CPP derived from the HIV-1 protein Tat is a cationic peptide. The majority of cationic peptides are naturally occurring peptide sequences. Recently, several artificial cationic peptides have been developed, includeing homo-polymers of arginine (<xref rid="b11-br-0-0-639" ref-type="bibr">11</xref>) and lysine (<xref rid="b12-br-0-0-639" ref-type="bibr">12</xref>). Studies on arginine-based peptides (from R3 to R12) have shown that the minimal sequence necessary for cellular uptake is six arginines, and that increasing the number of arginine residues increased transduction efficiency (<xref rid="b13-br-0-0-639" ref-type="bibr">13</xref>). In comparison, increasing the number of lysine residues reduced uptake of polylysine CPPs. However, arginine and lysine homopolymers &#x003E;12 amino acids show reduced transduction efficiency (<xref rid="b14-br-0-0-639" ref-type="bibr">14</xref>). Nuclear localization sequences (NLSs) are a special type of cationic CPPs, which facilitate translocation into the nucleus through the nuclear pore complex (<xref rid="b15-br-0-0-639" ref-type="bibr">15</xref>).</p>
</sec>
<sec>
<title>Amphipathic CPPs</title>
<p>Amphipathic CPPs are chimeric peptides, several of which are obtained by the covalent attachment of a hydrophobic domain to an NLS, such as MAP and MPG sequences (<xref rid="b16-br-0-0-639" ref-type="bibr">16</xref>). For example, MPG (GALFLGWLGAAGSTMGAPKKKRKV) is based on the SV40 NLS PKKRKV, and the hydrophobic domain derived from the fusion sequence of the HIV glycoprotein 41 (<xref rid="b17-br-0-0-639" ref-type="bibr">17</xref>). Several other primary amphipathic CPPs, such as pVEC (<xref rid="b18-br-0-0-639" ref-type="bibr">18</xref>), ARF (<xref rid="b1-br-0-0-639" ref-type="bibr">1</xref>&#x2013;<xref rid="b22-br-0-0-639" ref-type="bibr">22</xref>) (<xref rid="b19-br-0-0-639" ref-type="bibr">19</xref>), and BPrPp (<xref rid="b1-br-0-0-639" ref-type="bibr">1</xref>&#x2013;<xref rid="b28-br-0-0-639" ref-type="bibr">28</xref>) (<xref rid="b20-br-0-0-639" ref-type="bibr">20</xref>), are derived from natural proteins.</p>
<p>Amphipathic &#x03B1;-helix is the most common structural motif of numerous peptides and proteins. Amphipathic &#x03B1;-helical CPPs have a highly hydrophobic patch on one face, whereas the other face can be cationic, anionic or polar. An amphipathic &#x03B2;-sheet peptide is developed based on one hydrophobic and one hydrophilic stretch of amino acids exposed to the solvent. Studies on VT5 (DPKGDPKGVTVTVTVTVTGKGDPKPD) have shown that the formation of &#x03B2;-sheets is essential for its cellular uptake (<xref rid="b21-br-0-0-639" ref-type="bibr">21</xref>,<xref rid="b22-br-0-0-639" ref-type="bibr">22</xref>). Proline-rich CPPs are a family of CPPs with diverse sequences and structures. However, their common structure has a proline pyrrolidine template (<xref rid="b23-br-0-0-639" ref-type="bibr">23</xref>).</p>
</sec>
<sec>
<title>Hydrophobic CPPs</title>
<p>Hydrophobic CPPs are derived from signal peptide sequences and contain only apolar residues. These peptides include transportan (<xref rid="b24-br-0-0-639" ref-type="bibr">24</xref>), stapled peptides (<xref rid="b25-br-0-0-639" ref-type="bibr">25</xref>), prenylated peptides (<xref rid="b26-br-0-0-639" ref-type="bibr">26</xref>) and pepducins (<xref rid="b27-br-0-0-639" ref-type="bibr">27</xref>). Thus far, only a few hydrophobic CPPs, including SG3 (<xref rid="b28-br-0-0-639" ref-type="bibr">28</xref>), Pep-7 (<xref rid="b29-br-0-0-639" ref-type="bibr">29</xref>), and fibroblast-growth factor (<xref rid="b30-br-0-0-639" ref-type="bibr">30</xref>), have been reported. Compared to cationic and amphipathic peptides, the potential application and mechanism of hydrophobic CPP translocation are less studied.</p>
</sec>
</sec>
</sec>
<sec>
<label>3.</label>
<title>Uptake mechanism of cell-penetrating peptides</title>
<p>The intracellular CPP uptake mechanism has remained elusive since the discovery that Tat was cell permeable. Although the exact mechanism of entrance of CPPs into cells has not been completely resolved (<xref rid="b31-br-0-0-639" ref-type="bibr">31</xref>&#x2013;<xref rid="b33-br-0-0-639" ref-type="bibr">33</xref>), it is widely believed that the CPP uptake mechanism varies for different CPP families, and the majority of CPPs have two or more pathways depending on the experimental conditions. Recent advances have shown that that there are three mechanisms for CPP translocation across the cellular membrane (<xref rid="tII-br-0-0-639" ref-type="table">Table II</xref>) (<xref rid="b34-br-0-0-639" ref-type="bibr">34</xref>,<xref rid="b35-br-0-0-639" ref-type="bibr">35</xref>).</p>
<sec>
<title/>
<sec>
<title>Direct penetration</title>
<p>The direct penetration pathway is energy-independent. Early studies showed that Tat and pAntp can enter a cell at 4&#x00B0;C (<xref rid="b36-br-0-0-639" ref-type="bibr">36</xref>,<xref rid="b37-br-0-0-639" ref-type="bibr">37</xref>). Veach <italic>et al</italic> (<xref rid="b38-br-0-0-639" ref-type="bibr">38</xref>) reported that Tat has the same cell-penetrating efficiency at 4 and 37&#x00B0;C, and the internalization process is not blocked in cells without adenosine triphosphate. In order to prove this mechanism, certain membrane models have been constructed, such as transient pore formation (<xref rid="b39-br-0-0-639" ref-type="bibr">39</xref>), the carpet-like model (<xref rid="b40-br-0-0-639" ref-type="bibr">40</xref>) and the membrane-thinning model (<xref rid="b41-br-0-0-639" ref-type="bibr">41</xref>). The common features of these models are that CPPs first bind to the cell membrane via electrostatic or hydrophobic interactions and induce a brief or prolonged membrane destabilization of the binding sites, leading to CPP entrance into the cells. The internalization coefficient is relative to the peptide concentration, peptide sequence and lipid composition in each model.</p>
</sec>
<sec>
<title>Endocytosis-mediated translocation</title>
<p>Unlike direct penetration, this pathway is energy-dependent. During the course of endocytosis-mediated translocation, cells obtain energy from outside of the membrane. Richard <italic>et al</italic> (<xref rid="b42-br-0-0-639" ref-type="bibr">42</xref>) studied the mechanisms of Tat and polyarginine translocation using fluorescence microscopy in living cells. They found that Tat and polyarginine enter into the cells via endocytosis. This transduction mechanism is further divided into two classes of endoycytosis: Phagocytosis and pinocytosis. Phagocytosis is used for absorption of large particles and pinocytosis is used for solute absorption (<xref rid="b32-br-0-0-639" ref-type="bibr">32</xref>). Pinocytosis exists in all cell types. Endocytosis of CPP as macropinocytosis, clathrin-dependent pathway, cholesterol-dependent clathrin-mediated pathway and caveolin/clathrin-independent pathway has been reported (<xref rid="b43-br-0-0-639" ref-type="bibr">43</xref>&#x2013;<xref rid="b45-br-0-0-639" ref-type="bibr">45</xref>).</p>
</sec>
<sec>
<title>Translocation via the formation of a transitory membrane structure</title>
<p>The translocation via the formation of a transitory membrane structure mechanism depends on the structure of inverted micelles to allow the peptide to bind a hydrophilic environment (<xref rid="b46-br-0-0-639" ref-type="bibr">46</xref>). In this model, a penetrating dimer combines with the negatively charged phospholipids leading to the formation of an inverted micelle inside the lipid bilayer (<xref rid="b9-br-0-0-639" ref-type="bibr">9</xref>). Arginine-rich peptides permeate the plasma membrane via this pathway (<xref rid="b47-br-0-0-639" ref-type="bibr">47</xref>).</p>
<p>Taken together, the CPP uptake mechanism remains largely unknown (<xref rid="b43-br-0-0-639" ref-type="bibr">43</xref>). The mechanism of CPP uptake may vary considerably according to CPP, CPP-cargo, cell types and concentration (<xref rid="b17-br-0-0-639" ref-type="bibr">17</xref>,<xref rid="b48-br-0-0-639" ref-type="bibr">48</xref>,<xref rid="b49-br-0-0-639" ref-type="bibr">49</xref>). Additionally, physicochemical parameters, incubation temperature and time should also be considered (<xref rid="b50-br-0-0-639" ref-type="bibr">50</xref>,<xref rid="b51-br-0-0-639" ref-type="bibr">51</xref>). Endocytosis is believed to be the dominant mechanism for the majority of CPP uptake. However, it is most likely that different transduction mechanisms may contribute under different conditions for the majority, if not all, CPPs.</p>
</sec>
</sec>
</sec>
<sec>
<label>4.</label>
<title>Application of cell-penetrating peptides</title>
<p>CPPs have the capability to deliver various cargoes without causing any cellular injury. Thus, a wide range of CPP applications are being developed, such as imaging agents and vehicles to deliver therapeutic drugs, small interfering RNA (siRNA), nucleotides, proteins and peptides. The main applications of CPPs are shown in <xref rid="tIII-br-0-0-639" ref-type="table">Table III</xref>.</p>
<sec>
<title/>
<sec>
<title>Imaging</title>
<p>Intracellular imaging has potential to improve disease management by detecting disease markers, but its application is limited due to the poor permeability of proteins. CPPs can function as vectors to carry fluorescent particles into cells due to their internalization properties and have become promising tools for delivering imaging agents, contrast agents and quantum dots (QDs) in the field of imaging. The advantage of such imaging technology is the ability to visualize and quantify biomarkers or biochemical and cellular processes, detect the stage of diseases, identify the extent of disease and measure the effect of treatment (<xref rid="b52-br-0-0-639" ref-type="bibr">52</xref>,<xref rid="b53-br-0-0-639" ref-type="bibr">53</xref>).</p>
<p>The size of QDs generally falls within the 2&#x2013;10 nanometer range; QDs are brighter and more stable against photobleaching than standard fluorescent indicators, and thus QDs have emerged as an alternative to organic dyes and fluorescent proteins (<xref rid="b54-br-0-0-639" ref-type="bibr">54</xref>). QDs have been extensively studied for biological imaging, but their inability to cross the cellular membrane has limited their application. This limitation has been overcome by the discovery of CPPs. Ruan <italic>et al</italic> (<xref rid="b55-br-0-0-639" ref-type="bibr">55</xref>) used Tat peptide-conjugated QDs (Tat-QDs) to examine the complex behavior of nanoparticle probes in live cells and found that Tat-QDs are internalized by macropinocytosis. The internalized Tat-QDs are tethered to the inner vesicle surfaces and are trapped in cytoplasmic organelles. The study also revealed that Tat-QDs strongly bind to cellular membrane structures. Their research provides new insights for molecular imaging and targeted therapy. In another study, Tat-QDs were efficiently introduced into living mesenchymal stem cells (<xref rid="b56-br-0-0-639" ref-type="bibr">56</xref>). Other imaging applications of CPPs have also been developed. The Gd-DOTA-D-Tat peptide conjugate can enter into the cell interior resulting in intracellular T1 relaxation enhancement (<xref rid="b57-br-0-0-639" ref-type="bibr">57</xref>); Tat-(99m)Tc conjugates can be applied for imaging and radiotherapy (<xref rid="b58-br-0-0-639" ref-type="bibr">58</xref>). Tat-(99m)Tc conjugates have also been developed for imaging in prostate and breast cancer (<xref rid="b59-br-0-0-639" ref-type="bibr">59</xref>,<xref rid="b60-br-0-0-639" ref-type="bibr">60</xref>). A hydrogen peroxide-activated CPP was developed to observe in vivo lung inflammation, suggesting that CPPs have the potential for imaging and treating diseases related to oxidative stress (<xref rid="b61-br-0-0-639" ref-type="bibr">61</xref>).</p>
</sec>
<sec>
<title>Anti-inflammation therapy</title>
<p>Antisense peptide nucleic acids (PNAs) have been shown to specifically inhibit gene expression and growth of Escherichia coli, and are a promising anti-inflammatroy agent (<xref rid="b62-br-0-0-639" ref-type="bibr">62</xref>). Accordingly, PNA conjugated with CPPs (CPP-PNA) have been developed for efficient delivery of PNAs (<xref rid="b63-br-0-0-639" ref-type="bibr">63</xref>). For example, administration of the acpP-targeting PNA conjugated to CPP into <italic>Escherichia coli</italic> K-12-infected BALB/c mice reduced bacterial blood contents, prevented fatal infection and enhanced survival of the infected mice (<xref rid="b64-br-0-0-639" ref-type="bibr">64</xref>). Similar results were observed for the CPP-PMO conjugate targeted to the same acpP administered to mice infected with <italic>Escherichia coli</italic> (<xref rid="b65-br-0-0-639" ref-type="bibr">65</xref>). The results demonstrated an antibiotic effect of these CPP-PNA conjugates.</p>
<p>Nuclear factor-&#x03BA;B (NF-&#x03BA;B) has an important role in the inflammation response. Inflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin-1 (IL-1), can activate NF-&#x03BA;B and induce the inflammatory reaction. It has been well documented that certain inflammatory diseases, such as rheumatoid arthritis (<xref rid="b66-br-0-0-639" ref-type="bibr">66</xref>), atherosclerosis (<xref rid="b67-br-0-0-639" ref-type="bibr">67</xref>), Parkinson&#x0027;s disease (<xref rid="b68-br-0-0-639" ref-type="bibr">68</xref>) and inflammatory bowel disorders (IBD) (<xref rid="b69-br-0-0-639" ref-type="bibr">69</xref>), are associated with the activation of NF-&#x03BA;B. IBD in particular is characterized by sustained upregulation of inflammatory factors, such as TNF-&#x03B1;, IL-6 and IL-1, accompanied by increased activity of NF-&#x03BA;B. It has been proposed that blocking the activation of NF-&#x03BA;B can prevent certain chronic inflammation (<xref rid="b70-br-0-0-639" ref-type="bibr">70</xref>). The NEMO binding domain (NBD) of IKK can block NF-&#x03BA;B activation. In a mouse model of IBD, intraperitoneal injection of CPP-NBD resulted in downregulation of inflammatory factors and amelioration of the disease (<xref rid="b71-br-0-0-639" ref-type="bibr">71</xref>), suggesting that CPP-NBD may be used in the treatment of IBD. In another study, intraperitoneal injection of Antp-NBD fusion peptide in a Duchenne muscular dystrophy mouse model decreased NF-&#x03BA;B activation and muscle necrosis, and increased muscle regeneration (<xref rid="b72-br-0-0-639" ref-type="bibr">72</xref>).</p>
</sec>
<sec>
<title>Tumor therapy</title>
<p>Cancer is an important public health issue and has become the leading killer of human beings (<xref rid="b73-br-0-0-639" ref-type="bibr">73</xref>). Conventional chemotherapy has a low drug concentration at local tumor areas and can cause severe side effects due to lack of tumor cell specificity (<xref rid="b74-br-0-0-639" ref-type="bibr">74</xref>). New efficient and tumor targeting strategies should be developed to overcome this limitation. Conjugation of anticancer agents with CPPs has improved tumor therapy. CPP-delivered anticancer therapeutics can increase cellular membrane permeability of anticancer drugs to target tumor cells, expanding the broad application of CPPs in tumor therapy (<xref rid="b75-br-0-0-639" ref-type="bibr">75</xref>). Bleomycin (BLM) is an anticancer drug that has been used extensively, but its efficiency depends on its cytosolic accumulation. The artificial R8-DOPE-BLM conjugate can enter into the cytosol and cause a stronger induction of tumor cell death and DNA damage in vitro compared to BLM (<xref rid="b76-br-0-0-639" ref-type="bibr">76</xref>). Elastin-like polypeptide (ELP) can passively accumulate in solid tumors and aggregate in tumor tissue when exposed to hyperthermia. Injection of a conjugate of doxorubicin with ELP and CPP in a C57BL/6 mouse breast cancer model resulted in augmented internalization of doxorubicin and reduced tumor size more than two-fold compared to free doxorubicin (<xref rid="b77-br-0-0-639" ref-type="bibr">77</xref>). Similar results have been obtained by conjugation of CPP with doxirubicin (<xref rid="b78-br-0-0-639" ref-type="bibr">78</xref>), Taxol (<xref rid="b79-br-0-0-639" ref-type="bibr">79</xref>) and methotrexate (<xref rid="b80-br-0-0-639" ref-type="bibr">80</xref>). These data demonstrate that CPP-delivered anticancer agents can improve drug concentration at the tumor tissue and increase the treatment effect.</p>
</sec>
<sec>
<title>Nucleic acid and protein delivery</title>
<p>Larger macromolecules, such as nucleic acids and proteins, are unable to penetrate the plasma membrane and enter into cells. CPPs can facilitate cellular uptake of large molecules and have been developed as a delivery tool for nucleic acids and proteins. siRNA have been widely used for gene silencing and used to treat diseases such as cancer, infectious diseases and genetic disorders (<xref rid="b81-br-0-0-639" ref-type="bibr">81</xref>). CPPs can overcome the barrier of poor permeability and lead to the internalization of siRNA (<xref rid="b21-br-0-0-639" ref-type="bibr">21</xref>). A CPP-siRNA complex synthesized via a disulfide bond has been shown to efficiently reduce transient and stable expression of reporter transgenes in several mammalian cell types (<xref rid="b82-br-0-0-639" ref-type="bibr">82</xref>), suggesting that CPP-siRNA has a potential application in siRNA-based therapy.</p>
<p>Recently, CPPs have also been conjugated to protein. A modular protein (T-Rp3) fused to an N-terminal DNA-binding domain and a C-terminal membrane Tat peptide was successfully expressed in <italic>Escherichia coli</italic>. Treatment of HeLa cells with this purified recombinant protein improved the delivery of T-Rp3 (<xref rid="b83-br-0-0-639" ref-type="bibr">83</xref>). Similarly, N-stearylated peptide has a low transfection activity; however, an N-terminal stearylated NLS (PKKKRKV) conjugated to CPP effectively promoted the nuclear translocation of N-stearylated peptide (<xref rid="b84-br-0-0-639" ref-type="bibr">84</xref>).</p>
</sec>
<sec>
<title>Viral delivery</title>
<p>CPPs can also be applied to enhance the efficiency of viral transduction (<xref rid="b85-br-0-0-639" ref-type="bibr">85</xref>). Adenoviral vector (Adv) has been extensively used in basic and clinical research due to its high transduction efficiency. However, Adv has poor infection efficiency in cells lacking the primary adenovirus receptor, as well as the coxsackievirus receptor (<xref rid="b86-br-0-0-639" ref-type="bibr">86</xref>). Adv bound to CPP can overcome this barrier (<xref rid="b87-br-0-0-639" ref-type="bibr">87</xref>). Adv conjugated to CPPs (CPP-Adv) by chemical conjugation results in higher gene expression, indicating that CPP-modified Adv as a delivery vector is an attractive tool for transducing cells and gene therapy (<xref rid="b86-br-0-0-639" ref-type="bibr">86</xref>).</p>
</sec>
<sec>
<title>Directing induced pluripotent stem cells (iPS) differentiation</title>
<p>iPS generated directly from somatic cells can differentiate into various cell types (<xref rid="b88-br-0-0-639" ref-type="bibr">88</xref>). Delivering certain molecules into iPS cells can direct cell-type specific differentiation, which can be used for disease modeling, drug screening and cell transplantation therapies (<xref rid="b89-br-0-0-639" ref-type="bibr">89</xref>). However, these applications are limited as iPS cells are generally difficult to transfect. Previous studies have shown that transfecting certain cytokines and growth factors can promote human iPS cell differentiation into lung (<xref rid="b90-br-0-0-639" ref-type="bibr">90</xref>) and retinal cells (<xref rid="b91-br-0-0-639" ref-type="bibr">91</xref>), but these delivery tools are lentiviral or Advs. Viral vectors can infect iPS cells, but present a risk of genomic integration of exogenous viral genes (<xref rid="b92-br-0-0-639" ref-type="bibr">92</xref>). Plasmid DNA transfection with cationic lipids can overcome this risk; however, the transfection efficiency is relatively low (<xref rid="b93-br-0-0-639" ref-type="bibr">93</xref>). CPP may be a powerful tool for delivering exogenous proteins into iPS cells, eliminating the risk of exogenous genomic integration, while promoting high transduction efficiency.</p>
</sec>
</sec>
</sec>
<sec sec-type="conclusions">
<label>5.</label>
<title>Conclusion</title>
<p>CPPs are a class of small peptides 5&#x2013;30 amino acids in length that have the potential to transport numerous types of therapeutic agents across the cellular membrane into cells. However, cellular CPP uptake mechanisms remain to be elucidated. CPPs have been widely used as a delivery vector due to their high transduction efficiency and capacity for delivering large molecules into a cell. CPPs are used to deliver fluorescent proteins to detect disease markers and manage disease. CPPs as vectors delivering therapeutic agents have proved effective in certain disease models, such as inflammatory disease and cancer. Additionally, CPPs can transport certain molecules into iPS cells to direct iPS cell-type specific differentiation. In conclusion, the application of CPPs for delivering a variety of agents into cells has promising clinical potential.</p>
<p>However, although there is a potential for CPP applications as diagnostic or therapeutic agents, there are no published human studies supporting their use. Several limitations should be addressed prior to using CPP-based diagnostic and therapeutics applications in the clinic. First, the best route of drug administration is oral uptake; however, there have been no detailed studies on the oral bioavailability of CPPs. Second, the majority of the reported CPPs are not tissue and organ-specific, which may cause severe side effects. Screening specific CPPs via a phage-display library may solve this problem. Additionally, kidney and liver toxicity should be considered as a new drug or therapeutic application.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The present study was supported by the National Natural Science Foundation of China (grant no. 81201297) and Chinese PLA project (grant no. 13QNP012).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-br-0-0-639"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindgren</surname><given-names>M</given-names></name><name><surname>Hallbrink</surname><given-names>M</given-names></name><name><surname>Prochiantz</surname><given-names>A</given-names></name><name><surname>Langel</surname><given-names>U</given-names></name></person-group><article-title>Cell-penetrating peptides</article-title><source>Trends Pharmacol Sci</source><volume>21</volume><fpage>99</fpage><lpage>103</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0165-6147(00)01447-4</pub-id><pub-id pub-id-type="pmid">10689363</pub-id></element-citation></ref>
<ref id="b2-br-0-0-639"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Loewenstein</surname><given-names>PM</given-names></name></person-group><article-title>Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein</article-title><source>Cell</source><volume>55</volume><fpage>1179</fpage><lpage>1188</lpage><year>1988</year><pub-id pub-id-type="doi">10.1016/0092-8674(88)90262-0</pub-id><pub-id pub-id-type="pmid">2849509</pub-id></element-citation></ref>
<ref id="b3-br-0-0-639"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankel</surname><given-names>AD</given-names></name><name><surname>Pabo</surname><given-names>CO</given-names></name></person-group><article-title>Cellular uptake of the tat protein from human immunodeficiency virus</article-title><source>Cell</source><volume>55</volume><fpage>1189</fpage><lpage>1193</lpage><year>1988</year><pub-id pub-id-type="doi">10.1016/0092-8674(88)90263-2</pub-id><pub-id pub-id-type="pmid">2849510</pub-id></element-citation></ref>
<ref id="b4-br-0-0-639"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joliot</surname><given-names>A</given-names></name><name><surname>Pernelle</surname><given-names>C</given-names></name><name><surname>Deagostini-Bazin</surname><given-names>H</given-names></name><name><surname>Prochiantz</surname><given-names>A</given-names></name></person-group><article-title>Antennapedia homeobox peptide regulates neural morphogenesis</article-title><source>Proc Natl Acad Sci USA</source><volume>88</volume><fpage>1864</fpage><lpage>1868</lpage><year>1991</year><pub-id pub-id-type="doi">10.1073/pnas.88.5.1864</pub-id><pub-id pub-id-type="pmid">1672046</pub-id></element-citation></ref>
<ref id="b5-br-0-0-639"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>G</given-names></name><name><surname>O&#x0027;Hare</surname><given-names>P</given-names></name></person-group><article-title>Intercellular trafficking and protein delivery by a herpesvirus structural protein</article-title><source>Cell</source><volume>88</volume><fpage>223</fpage><lpage>233</lpage><year>1997</year><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81843-7</pub-id><pub-id pub-id-type="pmid">9008163</pub-id></element-citation></ref>
<ref id="b6-br-0-0-639"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fawell</surname><given-names>S</given-names></name><name><surname>Seery</surname><given-names>J</given-names></name><name><surname>Daikh</surname><given-names>Y</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><name><surname>Pepinsky</surname><given-names>B</given-names></name><name><surname>Barsoum</surname><given-names>J</given-names></name></person-group><article-title>Tat-mediated delivery of heterologous proteins into cells</article-title><source>Proc Natl Acad Sci USA</source><volume>91</volume><fpage>664</fpage><lpage>668</lpage><year>1994</year><pub-id pub-id-type="doi">10.1073/pnas.91.2.664</pub-id><pub-id pub-id-type="pmid">8290579</pub-id></element-citation></ref>
<ref id="b7-br-0-0-639"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewin</surname><given-names>M</given-names></name><name><surname>Carlesso</surname><given-names>N</given-names></name><name><surname>Tung</surname><given-names>CH</given-names></name><name><surname>Tang</surname><given-names>XW</given-names></name><name><surname>Cory</surname><given-names>D</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name></person-group><article-title>Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells</article-title><source>Nat Biotechnol</source><volume>18</volume><fpage>410</fpage><lpage>414</lpage><year>2000</year><pub-id pub-id-type="doi">10.1038/74464</pub-id><pub-id pub-id-type="pmid">10748521</pub-id></element-citation></ref>
<ref id="b8-br-0-0-639"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>McBride</surname><given-names>JL</given-names></name><name><surname>Jung</surname><given-names>KE</given-names></name><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Davidson</surname><given-names>BL</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Shankar</surname><given-names>P</given-names></name><name><surname>Manjunath</surname><given-names>N</given-names></name></person-group><article-title>Transvascular delivery of small interfering RNA to the central nervous system</article-title><source>Nature</source><volume>448</volume><fpage>39</fpage><lpage>43</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/nature05901</pub-id><pub-id pub-id-type="pmid">17572664</pub-id></element-citation></ref>
<ref id="b9-br-0-0-639"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafari</surname><given-names>S</given-names></name><name><surname>Maleki</surname><given-names>Dizaj S</given-names></name><name><surname>Adibkia</surname><given-names>K</given-names></name></person-group><article-title>Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery</article-title><source>Bioimpacts</source><volume>5</volume><fpage>103</fpage><lpage>111</lpage><year>2015</year><pub-id pub-id-type="doi">10.15171/bi.2015.10</pub-id><pub-id pub-id-type="pmid">26191505</pub-id></element-citation></ref>
<ref id="b10-br-0-0-639"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milletti</surname><given-names>F</given-names></name></person-group><article-title>Cell-penetrating peptides: Classes, origin, and current landscape</article-title><source>Drug Discov Today</source><volume>17</volume><fpage>850</fpage><lpage>860</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.drudis.2012.03.002</pub-id><pub-id pub-id-type="pmid">22465171</pub-id></element-citation></ref>
<ref id="b11-br-0-0-639"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wender</surname><given-names>PA</given-names></name><name><surname>Mitchell</surname><given-names>DJ</given-names></name><name><surname>Pattabiraman</surname><given-names>K</given-names></name><name><surname>Pelkey</surname><given-names>ET</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name><name><surname>Rothbard</surname><given-names>JB</given-names></name></person-group><article-title>The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters</article-title><source>Proc Natl Acad Sci USA</source><volume>97</volume><fpage>13003</fpage><lpage>13008</lpage><year>2000</year><pub-id pub-id-type="doi">10.1073/pnas.97.24.13003</pub-id><pub-id pub-id-type="pmid">11087855</pub-id></element-citation></ref>
<ref id="b12-br-0-0-639"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>JC</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Watkins</surname><given-names>SC</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Robbins</surname><given-names>PD</given-names></name></person-group><article-title>Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate</article-title><source>J Biol Chem</source><volume>277</volume><fpage>30208</fpage><lpage>30218</lpage><year>2002</year><pub-id pub-id-type="doi">10.1074/jbc.M204202200</pub-id><pub-id pub-id-type="pmid">12034749</pub-id></element-citation></ref>
<ref id="b13-br-0-0-639"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunnemann</surname><given-names>G</given-names></name><name><surname>Ter-Avetisyan</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Stockl</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>A</given-names></name><name><surname>Cardoso</surname><given-names>MC</given-names></name></person-group><article-title>Live-cell analysis of cell penetration ability and toxicity of oligo-arginines</article-title><source>J Pept Sci</source><volume>14</volume><fpage>469</fpage><lpage>476</lpage><year>2008</year><pub-id pub-id-type="doi">10.1002/psc.968</pub-id><pub-id pub-id-type="pmid">18069724</pub-id></element-citation></ref>
<ref id="b14-br-0-0-639"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahid</surname><given-names>M</given-names></name><name><surname>Robbins</surname><given-names>PD</given-names></name></person-group><article-title>Cell-type specific penetrating peptides: Therapeutic promises and challenges</article-title><source>Molecules</source><volume>20</volume><fpage>13055</fpage><lpage>13070</lpage><year>2015</year><pub-id pub-id-type="doi">10.3390/molecules200713055</pub-id><pub-id pub-id-type="pmid">26205050</pub-id></element-citation></ref>
<ref id="b15-br-0-0-639"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragin</surname><given-names>AD</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Chmielewski</surname><given-names>J</given-names></name></person-group><article-title>Cellular import mediated by nuclear localization signal Peptide sequences</article-title><source>Chem Biol</source><volume>9</volume><fpage>943</fpage><lpage>948</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S1074-5521(02)00189-8</pub-id><pub-id pub-id-type="pmid">12204694</pub-id></element-citation></ref>
<ref id="b16-br-0-0-639"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oehlke</surname><given-names>J</given-names></name><name><surname>Scheller</surname><given-names>A</given-names></name><name><surname>Wiesner</surname><given-names>B</given-names></name><name><surname>Krause</surname><given-names>E</given-names></name><name><surname>Beyermann</surname><given-names>M</given-names></name><name><surname>Klauschenz</surname><given-names>E</given-names></name><name><surname>Melzig</surname><given-names>M</given-names></name><name><surname>Bienert</surname><given-names>M</given-names></name></person-group><article-title>Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically</article-title><source>Biochim Biophys Acta</source><volume>1414</volume><fpage>127</fpage><lpage>139</lpage><year>1998</year><pub-id pub-id-type="doi">10.1016/S0005-2736(98)00161-8</pub-id><pub-id pub-id-type="pmid">9804921</pub-id></element-citation></ref>
<ref id="b17-br-0-0-639"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshayes</surname><given-names>S</given-names></name><name><surname>Pl&#x00E9;nat</surname><given-names>T</given-names></name><name><surname>Aldrian-Herrada</surname><given-names>G</given-names></name><name><surname>Divita</surname><given-names>G</given-names></name><name><surname>Le Grimellec</surname><given-names>C</given-names></name><name><surname>Heitz</surname><given-names>F</given-names></name></person-group><article-title>Primary amphipathic cell-penetrating peptides: Structural requirements and interactions with model membranes</article-title><source>Biochemistry</source><volume>43</volume><fpage>7698</fpage><lpage>7706</lpage><year>2004</year><pub-id pub-id-type="doi">10.1021/bi049298m</pub-id><pub-id pub-id-type="pmid">15196012</pub-id></element-citation></ref>
<ref id="b18-br-0-0-639"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nan</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>IS</given-names></name><name><surname>Hahm</surname><given-names>KS</given-names></name><name><surname>Shin</surname><given-names>SY</given-names></name></person-group><article-title>Antimicrobial activity, bactericidal mechanism and LPS-neutralizing activity of the cell-penetrating peptide pVEC and its analogs</article-title><source>J Pept Sci</source><volume>17</volume><fpage>812</fpage><lpage>817</lpage><year>2011</year><pub-id pub-id-type="doi">10.1002/psc.1408</pub-id><pub-id pub-id-type="pmid">21956793</pub-id></element-citation></ref>
<ref id="b19-br-0-0-639"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>HJ</given-names></name><name><surname>El-Andaloussi</surname><given-names>S</given-names></name><name><surname>Holm</surname><given-names>T</given-names></name><name><surname>M&#x00E4;e</surname><given-names>M</given-names></name><name><surname>J&#x00E4;nes</surname><given-names>J</given-names></name><name><surname>Maimets</surname><given-names>T</given-names></name><name><surname>Langel</surname><given-names>U</given-names></name></person-group><article-title>Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein</article-title><source>Mol Ther</source><volume>16</volume><fpage>115</fpage><lpage>123</lpage><year>2008</year><pub-id pub-id-type="doi">10.1038/sj.mt.6300346</pub-id><pub-id pub-id-type="pmid">17984975</pub-id></element-citation></ref>
<ref id="b20-br-0-0-639"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magzoub</surname><given-names>M</given-names></name><name><surname>Sandgren</surname><given-names>S</given-names></name><name><surname>Lundberg</surname><given-names>P</given-names></name><name><surname>Oglecka</surname><given-names>K</given-names></name><name><surname>Lilja</surname><given-names>J</given-names></name><name><surname>Wittrup</surname><given-names>A</given-names></name><name><surname>Eriksson</surname><given-names>G&#x00F6;ran LE</given-names></name><name><surname>Langel</surname><given-names>U</given-names></name><name><surname>Belting</surname><given-names>M</given-names></name><name><surname>Gr&#x00E4;slund</surname><given-names>A</given-names></name></person-group><article-title>N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis</article-title><source>Biochem Biophys Res Commun</source><volume>348</volume><fpage>379</fpage><lpage>385</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2006.07.065</pub-id><pub-id pub-id-type="pmid">16893522</pub-id></element-citation></ref>
<ref id="b21-br-0-0-639"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eguchi</surname><given-names>A</given-names></name><name><surname>Dowdy</surname><given-names>SF</given-names></name></person-group><article-title>siRNA delivery using peptide transduction domains</article-title><source>Trends Pharmacol Sci</source><volume>30</volume><fpage>341</fpage><lpage>345</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.tips.2009.04.009</pub-id><pub-id pub-id-type="pmid">19545914</pub-id></element-citation></ref>
<ref id="b22-br-0-0-639"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oehlke</surname><given-names>J</given-names></name><name><surname>Krause</surname><given-names>E</given-names></name><name><surname>Wiesner</surname><given-names>B</given-names></name><name><surname>Beyermann</surname><given-names>M</given-names></name><name><surname>Bienert</surname><given-names>M</given-names></name></person-group><article-title>Extensive cellular uptake into endothelial cells of an amphipathic beta-sheet forming peptide</article-title><source>FEBS Lett</source><volume>415</volume><fpage>196</fpage><lpage>199</lpage><year>1997</year><pub-id pub-id-type="doi">10.1016/S0014-5793(97)01123-X</pub-id><pub-id pub-id-type="pmid">9350995</pub-id></element-citation></ref>
<ref id="b23-br-0-0-639"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pujals</surname><given-names>S</given-names></name><name><surname>Giralt</surname><given-names>E</given-names></name></person-group><article-title>Proline-rich, amphipathic cell-penetrating peptides</article-title><source>Adv Drug Deliv Rev</source><volume>60</volume><fpage>473</fpage><lpage>484</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.addr.2007.09.012</pub-id><pub-id pub-id-type="pmid">18187229</pub-id></element-citation></ref>
<ref id="b24-br-0-0-639"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pooga</surname><given-names>M</given-names></name><name><surname>H&#x00E4;llbrink</surname><given-names>M</given-names></name><name><surname>Zorko</surname><given-names>M</given-names></name><name><surname>Langel</surname><given-names>U</given-names></name></person-group><article-title>Cell penetration by transportan</article-title><source>FASEB J</source><volume>12</volume><fpage>67</fpage><lpage>77</lpage><year>1998</year><pub-id pub-id-type="pmid">9438412</pub-id></element-citation></ref>
<ref id="b25-br-0-0-639"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafmeister</surname><given-names>CE</given-names></name><name><surname>Po</surname><given-names>J</given-names></name><name><surname>Verdine</surname><given-names>GL</given-names></name></person-group><article-title>An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides</article-title><source>J Am Chem Soc</source><volume>122</volume><fpage>5891</fpage><lpage>5892</lpage><year>2000</year><pub-id pub-id-type="doi">10.1021/ja000563a</pub-id></element-citation></ref>
<ref id="b26-br-0-0-639"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochocki</surname><given-names>JD</given-names></name><name><surname>Mullen</surname><given-names>DG</given-names></name><name><surname>Wattenberg</surname><given-names>EV</given-names></name><name><surname>Distefano</surname><given-names>MD</given-names></name></person-group><article-title>Evaluation of a cell penetrating prenylated peptide lacking an intrinsic fluorophore via in situ click reaction</article-title><source>Bioorg Med Chem Lett</source><volume>21</volume><fpage>4998</fpage><lpage>5001</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.04.138</pub-id><pub-id pub-id-type="pmid">21632248</pub-id></element-citation></ref>
<ref id="b27-br-0-0-639"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covic</surname><given-names>L</given-names></name><name><surname>Gresser</surname><given-names>AL</given-names></name><name><surname>Talavera</surname><given-names>J</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Kuliopulos</surname><given-names>A</given-names></name></person-group><article-title>Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides</article-title><source>Proc Natl Acad Sci USA</source><volume>99</volume><fpage>643</fpage><lpage>648</lpage><year>2002</year><pub-id pub-id-type="doi">10.1073/pnas.022460899</pub-id><pub-id pub-id-type="pmid">11805322</pub-id></element-citation></ref>
<ref id="b28-br-0-0-639"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>MJ</given-names></name><name><surname>Hue</surname><given-names>CD</given-names></name><name><surname>Morrison</surname><given-names>B</given-names><suffix>III</suffix></name><name><surname>Banta</surname><given-names>S</given-names></name></person-group><article-title>An unusual cell penetrating peptide identified using a plasmid display-based functional selection platform</article-title><source>ACS Chem Biol</source><volume>6</volume><fpage>484</fpage><lpage>491</lpage><year>2011</year><pub-id pub-id-type="doi">10.1021/cb100423u</pub-id><pub-id pub-id-type="pmid">21291271</pub-id></element-citation></ref>
<ref id="b29-br-0-0-639"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Mao</surname><given-names>S</given-names></name><name><surname>Ditzel</surname><given-names>HJ</given-names></name><name><surname>Farnaes</surname><given-names>L</given-names></name><name><surname>Wirsching</surname><given-names>P</given-names></name><name><surname>Lerner</surname><given-names>RA</given-names></name><name><surname>Janda</surname><given-names>KD</given-names></name></person-group><article-title>A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library</article-title><source>Bioorg Med Chem</source><volume>10</volume><fpage>4057</fpage><lpage>4065</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S0968-0896(02)00340-1</pub-id><pub-id pub-id-type="pmid">12413859</pub-id></element-citation></ref>
<ref id="b30-br-0-0-639"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>F</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Umeda</surname><given-names>S</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Meineke</surname><given-names>V</given-names></name><name><surname>Akashi</surname><given-names>M</given-names></name></person-group><article-title>Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain: Involvement of internalization in the in vivo role of exogenous FGF12</article-title><source>J Biol Chem</source><volume>286</volume><fpage>25823</fpage><lpage>25834</lpage><year>2011</year><pub-id pub-id-type="doi">10.1074/jbc.M110.198267</pub-id><pub-id pub-id-type="pmid">21518765</pub-id></element-citation></ref>
<ref id="b31-br-0-0-639"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>SB</given-names></name><name><surname>Pereira</surname><given-names>MP</given-names></name><name><surname>Kelley</surname><given-names>SO</given-names></name></person-group><article-title>Recent advances in the use of cell-penetrating peptides for medical and biological applications</article-title><source>Adv Drug Deliv Rev</source><volume>61</volume><fpage>953</fpage><lpage>964</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.addr.2009.06.001</pub-id><pub-id pub-id-type="pmid">19538995</pub-id></element-citation></ref>
<ref id="b32-br-0-0-639"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madani</surname><given-names>F</given-names></name><name><surname>Lindberg</surname><given-names>S</given-names></name><name><surname>Langel</surname><given-names>U</given-names></name><name><surname>Futaki</surname><given-names>S</given-names></name><name><surname>Graslund</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms of cellular uptake of cell-penetrating peptides</article-title><source>J Biophys</source><volume>2011</volume><fpage>414729</fpage><year>2011</year><pub-id pub-id-type="pmid">21687343</pub-id></element-citation></ref>
<ref id="b33-br-0-0-639"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YS</given-names></name><name><surname>David</surname><given-names>AE</given-names></name></person-group><article-title>Cell penetrating peptides and the mechanisms for intracellular entry</article-title><source>Curr Pharm Biotechnol</source><volume>15</volume><fpage>192</fpage><lpage>199</lpage><year>2014</year><pub-id pub-id-type="doi">10.2174/1389201015666140617093331</pub-id><pub-id pub-id-type="pmid">24938895</pub-id></element-citation></ref>
<ref id="b34-br-0-0-639"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Gehring</surname><given-names>W</given-names></name></person-group><article-title>Cellular uptake of the Antennapedia homeodomain polypeptide by macropinocytosis</article-title><source>Biochem Biophys Res Commun</source><volume>443</volume><fpage>1136</fpage><lpage>1140</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.12.062</pub-id><pub-id pub-id-type="pmid">24361959</pub-id></element-citation></ref>
<ref id="b35-br-0-0-639"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polanco</surname><given-names>C</given-names></name><name><surname>Samaniego</surname><given-names>JL</given-names></name><name><surname>Casta&#x00F1;&#x00F3;n-Gonz&#x00E1;lez</surname><given-names>JA</given-names></name><name><surname>Buhse</surname><given-names>T</given-names></name><name><surname>Sordo</surname><given-names>ML</given-names></name></person-group><article-title>Characterization of a possible uptake mechanism of selective antibacterial peptides</article-title><source>Acta Biochim Pol</source><volume>60</volume><fpage>629</fpage><lpage>633</lpage><year>2013</year><pub-id pub-id-type="pmid">24432312</pub-id></element-citation></ref>
<ref id="b36-br-0-0-639"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viv&#x00E8;s</surname><given-names>E</given-names></name><name><surname>Brodin</surname><given-names>P</given-names></name><name><surname>Lebleu</surname><given-names>B</given-names></name></person-group><article-title>A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus</article-title><source>J Biol Chem</source><volume>272</volume><fpage>16010</fpage><lpage>16017</lpage><year>1997</year><pub-id pub-id-type="doi">10.1074/jbc.272.25.16010</pub-id><pub-id pub-id-type="pmid">9188504</pub-id></element-citation></ref>
<ref id="b37-br-0-0-639"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derossi</surname><given-names>D</given-names></name><name><surname>Joliot</surname><given-names>AH</given-names></name><name><surname>Chassaing</surname><given-names>G</given-names></name><name><surname>Prochiantz</surname><given-names>A</given-names></name></person-group><article-title>The third helix of the Antennapedia homeodomain translocates through biological membranes</article-title><source>J Biol Chem</source><volume>269</volume><fpage>10444</fpage><lpage>10450</lpage><year>1994</year><pub-id pub-id-type="pmid">8144628</pub-id></element-citation></ref>
<ref id="b38-br-0-0-639"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veach</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Downs</surname><given-names>S</given-names></name><name><surname>Hawiger</surname><given-names>J</given-names></name></person-group><article-title>Receptor/transporter-independent targeting of functional peptides across the plasma membrane</article-title><source>J Biol Chem</source><volume>279</volume><fpage>11425</fpage><lpage>11431</lpage><year>2004</year><pub-id pub-id-type="doi">10.1074/jbc.M311089200</pub-id><pub-id pub-id-type="pmid">14699109</pub-id></element-citation></ref>
<ref id="b39-br-0-0-639"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herce</surname><given-names>HD</given-names></name><name><surname>Garcia</surname><given-names>AE</given-names></name></person-group><article-title>Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes</article-title><source>Proc Natl Acad Sci USA</source><volume>104</volume><fpage>20805</fpage><lpage>20810</lpage><year>2007</year><pub-id pub-id-type="doi">10.1073/pnas.0706574105</pub-id><pub-id pub-id-type="pmid">18093956</pub-id></element-citation></ref>
<ref id="b40-br-0-0-639"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouny</surname><given-names>Y</given-names></name><name><surname>Rapaport</surname><given-names>D</given-names></name><name><surname>Mor</surname><given-names>A</given-names></name><name><surname>Nicolas</surname><given-names>P</given-names></name><name><surname>Shai</surname><given-names>Y</given-names></name></person-group><article-title>Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes</article-title><source>Biochemistry</source><volume>31</volume><fpage>12416</fpage><lpage>12423</lpage><year>1992</year><pub-id pub-id-type="doi">10.1021/bi00164a017</pub-id><pub-id pub-id-type="pmid">1463728</pub-id></element-citation></ref>
<ref id="b41-br-0-0-639"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MT</given-names></name><name><surname>Hung</surname><given-names>WC</given-names></name><name><surname>Chen</surname><given-names>FY</given-names></name><name><surname>Huang</surname><given-names>HW</given-names></name></person-group><article-title>Many-body effect of antimicrobial peptides: On the correlation between lipid&#x0027;s spontaneous curvature and pore formation</article-title><source>Biophys J</source><volume>89</volume><fpage>4006</fpage><lpage>4016</lpage><year>2005</year><pub-id pub-id-type="doi">10.1529/biophysj.105.068080</pub-id><pub-id pub-id-type="pmid">16150963</pub-id></element-citation></ref>
<ref id="b42-br-0-0-639"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>JP</given-names></name><name><surname>Melikov</surname><given-names>K</given-names></name><name><surname>Vives</surname><given-names>E</given-names></name><name><surname>Ramos</surname><given-names>C</given-names></name><name><surname>Verbeure</surname><given-names>B</given-names></name><name><surname>Gait</surname><given-names>MJ</given-names></name><name><surname>Chernomordik</surname><given-names>LV</given-names></name><name><surname>Lebleu</surname><given-names>B</given-names></name></person-group><article-title>Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake</article-title><source>J Biol Chem</source><volume>278</volume><fpage>585</fpage><lpage>590</lpage><year>2003</year><pub-id pub-id-type="doi">10.1074/jbc.M209548200</pub-id><pub-id pub-id-type="pmid">12411431</pub-id></element-citation></ref>
<ref id="b43-br-0-0-639"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viv&#x00E8;s</surname><given-names>E</given-names></name><name><surname>Schmidt</surname><given-names>J</given-names></name><name><surname>P&#x00E8;legrin</surname><given-names>A</given-names></name></person-group><article-title>Cell-penetrating and cell-targeting peptides in drug delivery</article-title><source>Biochim Biophys Acta</source><volume>1786</volume><fpage>126</fpage><lpage>138</lpage><year>2008</year><pub-id pub-id-type="pmid">18440319</pub-id></element-citation></ref>
<ref id="b44-br-0-0-639"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>AT</given-names></name></person-group><article-title>Macropinocytosis: Searching for an endocytic identity and role in the uptake of cell penetrating peptides</article-title><source>J Cell Mol Med</source><volume>11</volume><fpage>670</fpage><lpage>684</lpage><year>2007</year><pub-id pub-id-type="doi">10.1111/j.1582-4934.2007.00062.x</pub-id><pub-id pub-id-type="pmid">17760832</pub-id></element-citation></ref>
<ref id="b45-br-0-0-639"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayor</surname><given-names>S</given-names></name><name><surname>Parton</surname><given-names>RG</given-names></name><name><surname>Donaldson</surname><given-names>JG</given-names></name></person-group><article-title>Clathrin-independent pathways of endocytosis</article-title><source>Cold Spring Harb Perspect Biol</source><volume>6</volume><fpage>6</fpage><year>2014</year><pub-id pub-id-type="doi">10.1101/cshperspect.a016758</pub-id></element-citation></ref>
<ref id="b46-br-0-0-639"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derossi</surname><given-names>D</given-names></name><name><surname>Calvet</surname><given-names>S</given-names></name><name><surname>Trembleau</surname><given-names>A</given-names></name><name><surname>Brunissen</surname><given-names>A</given-names></name><name><surname>Chassaing</surname><given-names>G</given-names></name><name><surname>Prochiantz</surname><given-names>A</given-names></name></person-group><article-title>Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent</article-title><source>J Biol Chem</source><volume>271</volume><fpage>18188</fpage><lpage>18193</lpage><year>1996</year><pub-id pub-id-type="doi">10.1074/jbc.271.30.18188</pub-id><pub-id pub-id-type="pmid">8663410</pub-id></element-citation></ref>
<ref id="b47-br-0-0-639"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>S</given-names></name><name><surname>Takasu</surname><given-names>M</given-names></name><name><surname>Miyakawa</surname><given-names>T</given-names></name><name><surname>Morikawa</surname><given-names>R</given-names></name><name><surname>Oda</surname><given-names>T</given-names></name><name><surname>Futaki</surname><given-names>S</given-names></name><name><surname>Nagao</surname><given-names>H</given-names></name></person-group><article-title>Inverted micelle formation of cell-penetrating peptide studied by coarse-grained simulation: Importance of attractive force between cell-penetrating peptides and lipid head group</article-title><source>J Chem Phys</source><volume>134</volume><fpage>095103</fpage><year>2011</year><pub-id pub-id-type="doi">10.1063/1.3555531</pub-id><pub-id pub-id-type="pmid">21385001</pub-id></element-citation></ref>
<ref id="b48-br-0-0-639"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>T&#x00FC;nnemann</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Haupt</surname><given-names>S</given-names></name><name><surname>Patsch</surname><given-names>C</given-names></name><name><surname>Edenhofer</surname><given-names>F</given-names></name><name><surname>Cardoso</surname><given-names>MC</given-names></name></person-group><article-title>Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells</article-title><source>FASEB J</source><volume>20</volume><fpage>1775</fpage><lpage>1784</lpage><year>2006</year><pub-id pub-id-type="doi">10.1096/fj.05-5523com</pub-id><pub-id pub-id-type="pmid">16940149</pub-id></element-citation></ref>
<ref id="b49-br-0-0-639"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>P</given-names></name><name><surname>El-Andaloussi</surname><given-names>S</given-names></name><name><surname>S&#x00FC;tl&#x00FC;</surname><given-names>T</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Langel</surname><given-names>U</given-names></name></person-group><article-title>Delivery of short interfering RNA using endosomolytic cell-penetrating peptides</article-title><source>FASEB J</source><volume>21</volume><fpage>2664</fpage><lpage>2671</lpage><year>2007</year><pub-id pub-id-type="doi">10.1096/fj.06-6502com</pub-id><pub-id pub-id-type="pmid">17463227</pub-id></element-citation></ref>
<ref id="b50-br-0-0-639"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>AT</given-names></name><name><surname>Sayers</surname><given-names>EJ</given-names></name></person-group><article-title>Cell entry of cell penetrating peptides: tales of tails wagging dogs</article-title><source>J Control Release</source><volume>161</volume><fpage>582</fpage><lpage>591</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.04.003</pub-id><pub-id pub-id-type="pmid">22516088</pub-id></element-citation></ref>
<ref id="b51-br-0-0-639"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>J</given-names></name><name><surname>Kretzschmar</surname><given-names>I</given-names></name><name><surname>Volkmer</surname><given-names>R</given-names></name><name><surname>Boisguerin</surname><given-names>P</given-names></name></person-group><article-title>Comparison of cellular uptake using 22 CPPs in 4 different cell lines</article-title><source>Bioconjug Chem</source><volume>19</volume><fpage>2363</fpage><lpage>2374</lpage><year>2008</year><pub-id pub-id-type="doi">10.1021/bc800194e</pub-id><pub-id pub-id-type="pmid">19053306</pub-id></element-citation></ref>
<ref id="b52-br-0-0-639"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pysz</surname><given-names>MA</given-names></name><name><surname>Gambhir</surname><given-names>SS</given-names></name><name><surname>Willmann</surname><given-names>JK</given-names></name></person-group><article-title>Molecular imaging: Current status and emerging strategies</article-title><source>Clin Radiol</source><volume>65</volume><fpage>500</fpage><lpage>516</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.crad.2010.03.011</pub-id><pub-id pub-id-type="pmid">20541650</pub-id></element-citation></ref>
<ref id="b53-br-0-0-639"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condeelis</surname><given-names>J</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name></person-group><article-title>In vivo imaging in cancer</article-title><source>Cold Spring Harb Perspect Biol</source><volume>2</volume><fpage>a003848</fpage><year>2010</year><pub-id pub-id-type="doi">10.1101/cshperspect.a003848</pub-id><pub-id pub-id-type="pmid">20861158</pub-id></element-citation></ref>
<ref id="b54-br-0-0-639"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walling</surname><given-names>MA</given-names></name><name><surname>Novak</surname><given-names>JA</given-names></name><name><surname>Shepard</surname><given-names>JRE</given-names></name></person-group><article-title>Quantum dots for live cell and in vivo imaging</article-title><source>Int J Mol Sci</source><volume>10</volume><fpage>441</fpage><lpage>491</lpage><year>2009</year><pub-id pub-id-type="doi">10.3390/ijms10020441</pub-id><pub-id pub-id-type="pmid">19333416</pub-id></element-citation></ref>
<ref id="b55-br-0-0-639"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>G</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Marcus</surname><given-names>AI</given-names></name><name><surname>Nie</surname><given-names>S</given-names></name></person-group><article-title>Imaging and tracking of tat peptide-conjugated quantum dots in living cells: New insights into nanoparticle uptake, intracellular transport, and vesicle shedding</article-title><source>J Am Chem Soc</source><volume>129</volume><fpage>14759</fpage><lpage>14766</lpage><year>2007</year><pub-id pub-id-type="doi">10.1021/ja074936k</pub-id><pub-id pub-id-type="pmid">17983227</pub-id></element-citation></ref>
<ref id="b56-br-0-0-639"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Zou</surname><given-names>B</given-names></name></person-group><article-title>Applications of mesenchymal stem cells labeled with Tat peptide conjugated quantum dots to cell tracking in mouse body</article-title><source>Bioconjug Chem</source><volume>19</volume><fpage>421</fpage><lpage>427</lpage><year>2008</year><pub-id pub-id-type="doi">10.1021/bc0700685</pub-id><pub-id pub-id-type="pmid">18081241</pub-id></element-citation></ref>
<ref id="b57-br-0-0-639"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prantner</surname><given-names>AM</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Garbow</surname><given-names>JR</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name></person-group><article-title>Synthesis and characterization of a Gd-DOTA-D-permeation peptide for magnetic resonance relaxation enhancement of intracellular targets</article-title><source>Mol Imaging</source><volume>2</volume><fpage>333</fpage><lpage>341</lpage><year>2003</year><pub-id pub-id-type="doi">10.1162/153535003322750673</pub-id><pub-id pub-id-type="pmid">14717332</pub-id></element-citation></ref>
<ref id="b58-br-0-0-639"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polyakov</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Dahlheimer</surname><given-names>JL</given-names></name><name><surname>Pica</surname><given-names>CM</given-names></name><name><surname>Luker</surname><given-names>GD</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name></person-group><article-title>Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy</article-title><source>Bioconjug Chem</source><volume>11</volume><fpage>762</fpage><lpage>771</lpage><year>2000</year><pub-id pub-id-type="doi">10.1021/bc000008y</pub-id><pub-id pub-id-type="pmid">11087323</pub-id></element-citation></ref>
<ref id="b59-br-0-0-639"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jim&#x00E9;nez-Mancilla</surname><given-names>N</given-names></name><name><surname>Ferro-Flores</surname><given-names>G</given-names></name><name><surname>Santos-Cuevas</surname><given-names>C</given-names></name><name><surname>Ocampo-Garc&#x00ED;a</surname><given-names>B</given-names></name><name><surname>Luna-Guti&#x00E9;rrez</surname><given-names>M</given-names></name><name><surname>Azor&#x00ED;n-Vega</surname><given-names>E</given-names></name><name><surname>Isaac-Oliv&#x00E9;</surname><given-names>K</given-names></name><name><surname>Camacho-L&#x00F3;pez</surname><given-names>M</given-names></name><name><surname>Torres-Garc&#x00ED;a</surname><given-names>E</given-names></name></person-group><article-title>Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49&#x2013;57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells</article-title><source>J Labelled Comp Radiopharm</source><volume>56</volume><fpage>663</fpage><lpage>671</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/jlcr.3087</pub-id><pub-id pub-id-type="pmid">25196028</pub-id></element-citation></ref>
<ref id="b60-br-0-0-639"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Cuevas</surname><given-names>CL</given-names></name><name><surname>Ferro-Flores</surname><given-names>G</given-names></name><name><surname>Rojas-Calder&#x00F3;n</surname><given-names>EL</given-names></name><name><surname>Garc&#x00ED;a-Becerra</surname><given-names>R</given-names></name><name><surname>Ordaz-Rosado</surname><given-names>D</given-names></name><name><surname>de Arteaga Murphy</surname><given-names>C</given-names></name><name><surname>Pedraza-L&#x00F3;pez</surname><given-names>M</given-names></name></person-group><article-title>99mTc-N2S2-Tat (49&#x2013;57)-bombesin internalized in nuclei of prostate and breast cancer cells: Kinetics, dosimetry and effect on cellular proliferation</article-title><source>Nucl Med Commun</source><volume>32</volume><fpage>303</fpage><lpage>313</lpage><year>2011</year><pub-id pub-id-type="doi">10.1097/MNM.0b013e328341b27f</pub-id><pub-id pub-id-type="pmid">21304415</pub-id></element-citation></ref>
<ref id="b61-br-0-0-639"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstain</surname><given-names>R</given-names></name><name><surname>Savariar</surname><given-names>EN</given-names></name><name><surname>Felsen</surname><given-names>CN</given-names></name><name><surname>Tsien</surname><given-names>RY</given-names></name></person-group><article-title>In vivo targeting of hydrogen peroxide by activatable cell-penetrating peptides</article-title><source>J Am Chem Soc</source><volume>136</volume><fpage>874</fpage><lpage>877</lpage><year>2014</year><pub-id pub-id-type="doi">10.1021/ja411547j</pub-id><pub-id pub-id-type="pmid">24377760</pub-id></element-citation></ref>
<ref id="b62-br-0-0-639"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Good</surname><given-names>L</given-names></name><name><surname>Awasthi</surname><given-names>SK</given-names></name><name><surname>Dryselius</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>O</given-names></name><name><surname>Nielsen</surname><given-names>PE</given-names></name></person-group><article-title>Bactericidal antisense effects of peptide-PNA conjugates</article-title><source>Nat Biotechnol</source><volume>19</volume><fpage>360</fpage><lpage>364</lpage><year>2001</year><pub-id pub-id-type="doi">10.1038/86753</pub-id><pub-id pub-id-type="pmid">11283595</pub-id></element-citation></ref>
<ref id="b63-br-0-0-639"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshayes</surname><given-names>S</given-names></name><name><surname>Konate</surname><given-names>K</given-names></name><name><surname>Aldrian</surname><given-names>G</given-names></name><name><surname>Crombez</surname><given-names>L</given-names></name><name><surname>Heitz</surname><given-names>F</given-names></name><name><surname>Divita</surname><given-names>G</given-names></name></person-group><article-title>Structural polymorphism of non-covalent peptide-based delivery systems: Highway to cellular uptake</article-title><source>Biochim Biophys Acta</source><volume>1798</volume><fpage>2304</fpage><lpage>2314</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.bbamem.2010.06.005</pub-id><pub-id pub-id-type="pmid">20541523</pub-id></element-citation></ref>
<ref id="b64-br-0-0-639"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>XX</given-names></name><name><surname>Actor</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: Proof of principle using mouse intraperitoneal infection</article-title><source>Antimicrob Agents Chemother</source><volume>49</volume><fpage>3203</fpage><lpage>3207</lpage><year>2005</year><pub-id pub-id-type="doi">10.1128/AAC.49.8.3203-3207.2005</pub-id><pub-id pub-id-type="pmid">16048926</pub-id></element-citation></ref>
<ref id="b65-br-0-0-639"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilley</surname><given-names>LD</given-names></name><name><surname>Mellbye</surname><given-names>BL</given-names></name><name><surname>Puckett</surname><given-names>SE</given-names></name><name><surname>Iversen</surname><given-names>PL</given-names></name><name><surname>Geller</surname><given-names>BL</given-names></name></person-group><article-title>Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: Dose-response in mice infected with Escherichia coli</article-title><source>J Antimicrob Chemother</source><volume>59</volume><fpage>66</fpage><lpage>73</lpage><year>2007</year><pub-id pub-id-type="doi">10.1093/jac/dkl444</pub-id><pub-id pub-id-type="pmid">17079242</pub-id></element-citation></ref>
<ref id="b66-br-0-0-639"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarov</surname><given-names>SS</given-names></name></person-group><article-title>NF-kappa B in rheumatoid arthritis: A pivotal regulator of inflammation, hyperplasia, and tissue destruction</article-title><source>Arthritis Res</source><volume>3</volume><fpage>200</fpage><lpage>206</lpage><year>2001</year><pub-id pub-id-type="doi">10.1186/ar300</pub-id><pub-id pub-id-type="pmid">11438035</pub-id></element-citation></ref>
<ref id="b67-br-0-0-639"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JD</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Griffin</surname><given-names>G</given-names></name><name><surname>Federation</surname><given-names>AJ</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Bair</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>G</given-names></name><name><surname>Lichtman</surname><given-names>AH</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><etal/></person-group><article-title>NF-&#x03BA;B directs dynamic super enhancer formation in inflammation and atherogenesis</article-title><source>Mol Cell</source><volume>56</volume><fpage>219</fpage><lpage>231</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.molcel.2014.08.024</pub-id><pub-id pub-id-type="pmid">25263595</pub-id></element-citation></ref>
<ref id="b68-br-0-0-639"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunot</surname><given-names>S</given-names></name><name><surname>Brugg</surname><given-names>B</given-names></name><name><surname>Ricard</surname><given-names>D</given-names></name><name><surname>Michel</surname><given-names>PP</given-names></name><name><surname>Muriel</surname><given-names>MP</given-names></name><name><surname>Ruberg</surname><given-names>M</given-names></name><name><surname>Faucheux</surname><given-names>BA</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Hirsch</surname><given-names>EC</given-names></name></person-group><article-title>Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease</article-title><source>Proc Natl Acad Sci USA</source><volume>94</volume><fpage>7531</fpage><lpage>7536</lpage><year>1997</year><pub-id pub-id-type="doi">10.1073/pnas.94.14.7531</pub-id><pub-id pub-id-type="pmid">9207126</pub-id></element-citation></ref>
<ref id="b69-br-0-0-639"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Greten</surname><given-names>FR</given-names></name></person-group><article-title>NF-kappaB: Linking inflammation and immunity to cancer development and progression</article-title><source>Nat Rev Immunol</source><volume>5</volume><fpage>749</fpage><lpage>759</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/nri1703</pub-id><pub-id pub-id-type="pmid">16175180</pub-id></element-citation></ref>
<ref id="b70-br-0-0-639"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>MJ</given-names></name><name><surname>D&#x0027;Acquisto</surname><given-names>F</given-names></name><name><surname>Madge</surname><given-names>LA</given-names></name><name><surname>Gl&#x00F6;ckner</surname><given-names>J</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex</article-title><source>Science</source><volume>289</volume><fpage>1550</fpage><lpage>1554</lpage><year>2000</year><pub-id pub-id-type="doi">10.1126/science.289.5484.1550</pub-id><pub-id pub-id-type="pmid">10968790</pub-id></element-citation></ref>
<ref id="b71-br-0-0-639"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dav&#x00E9;</surname><given-names>SH</given-names></name><name><surname>Tilstra</surname><given-names>JS</given-names></name><name><surname>Matsuoka</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Karrasch</surname><given-names>T</given-names></name><name><surname>Uno</surname><given-names>JK</given-names></name><name><surname>Sepulveda</surname><given-names>AR</given-names></name><name><surname>Jobin</surname><given-names>C</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names></name><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Plevy</surname><given-names>SE</given-names></name></person-group><article-title>Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide</article-title><source>J Immunol</source><volume>179</volume><fpage>7852</fpage><lpage>7859</lpage><year>2007</year><pub-id pub-id-type="doi">10.4049/jimmunol.179.11.7852</pub-id><pub-id pub-id-type="pmid">18025231</pub-id></element-citation></ref>
<ref id="b72-br-0-0-639"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>JM</given-names></name><name><surname>Kline</surname><given-names>W</given-names></name><name><surname>Canan</surname><given-names>BD</given-names></name><name><surname>Ricca</surname><given-names>DJ</given-names></name><name><surname>Kaspar</surname><given-names>B</given-names></name><name><surname>Delf&#x00ED;n</surname><given-names>DA</given-names></name><name><surname>DiRienzo</surname><given-names>K</given-names></name><name><surname>Clemens</surname><given-names>PR</given-names></name><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Peptide-based inhibition of NF-&#x03BA;B rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy</article-title><source>Mol Med</source><volume>17</volume><fpage>508</fpage><lpage>515</lpage><year>2011</year><pub-id pub-id-type="doi">10.2119/molmed.2010.00263</pub-id><pub-id pub-id-type="pmid">21267511</pub-id></element-citation></ref>
<ref id="b73-br-0-0-639"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heged&#x00FC;s</surname><given-names>R</given-names></name><name><surname>Manea</surname><given-names>M</given-names></name><name><surname>Orb&#x00E1;n</surname><given-names>E</given-names></name><name><surname>Szab&#x00F3;</surname><given-names>I</given-names></name><name><surname>Kiss</surname><given-names>E</given-names></name><name><surname>Sipos</surname><given-names>E</given-names></name><name><surname>Halmos</surname><given-names>G</given-names></name><name><surname>Mez&#x0151;</surname><given-names>G</given-names></name></person-group><article-title>Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates</article-title><source>Eur J Med Chem</source><volume>56</volume><fpage>155</fpage><lpage>165</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.ejmech.2012.08.014</pub-id><pub-id pub-id-type="pmid">22967796</pub-id></element-citation></ref>
<ref id="b74-br-0-0-639"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title>Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles</article-title><source>Biomaterials</source><volume>34</volume><fpage>2719</fpage><lpage>2730</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.12.040</pub-id><pub-id pub-id-type="pmid">23337327</pub-id></element-citation></ref>
<ref id="b75-br-0-0-639"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>E</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Tashiro</surname><given-names>Y</given-names></name><name><surname>Kamide</surname><given-names>K</given-names></name><name><surname>Uno</surname><given-names>S</given-names></name><name><surname>Furuya</surname><given-names>T</given-names></name><name><surname>Mashita</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Tsumuraya</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems</article-title><source>Nat Commun</source><volume>3</volume><fpage>951</fpage><year>2012</year><pub-id pub-id-type="doi">10.1038/ncomms1952</pub-id><pub-id pub-id-type="pmid">22805558</pub-id></element-citation></ref>
<ref id="b76-br-0-0-639"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koshkaryev</surname><given-names>A</given-names></name><name><surname>Piroyan</surname><given-names>A</given-names></name><name><surname>Torchilin</surname><given-names>VP</given-names></name></person-group><article-title>Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition</article-title><source>Cancer Lett</source><volume>334</volume><fpage>293</fpage><lpage>301</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.canlet.2012.06.008</pub-id><pub-id pub-id-type="pmid">22743614</pub-id></element-citation></ref>
<ref id="b77-br-0-0-639"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>L</given-names></name><name><surname>Perkins</surname><given-names>E</given-names></name><name><surname>Kratz</surname><given-names>F</given-names></name><name><surname>Raucher</surname><given-names>D</given-names></name></person-group><article-title>Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative</article-title><source>Int J Pharm</source><volume>436</volume><fpage>825</fpage><lpage>832</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.07.043</pub-id><pub-id pub-id-type="pmid">22850291</pub-id></element-citation></ref>
<ref id="b78-br-0-0-639"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aroui</surname><given-names>S</given-names></name><name><surname>Mili</surname><given-names>D</given-names></name><name><surname>Brahim</surname><given-names>S</given-names></name><name><surname>De Waard</surname><given-names>M</given-names></name><name><surname>Kenani</surname><given-names>A</given-names></name></person-group><article-title>Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by a mechanism involving c-Jun NH2-terminal kinase</article-title><source>Biochem Biophys Res Commun</source><volume>396</volume><fpage>908</fpage><lpage>914</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.05.020</pub-id><pub-id pub-id-type="pmid">20457128</pub-id></element-citation></ref>
<ref id="b79-br-0-0-639"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubikovskaya</surname><given-names>EA</given-names></name><name><surname>Thorne</surname><given-names>SH</given-names></name><name><surname>Pillow</surname><given-names>TH</given-names></name><name><surname>Contag</surname><given-names>CH</given-names></name><name><surname>Wender</surname><given-names>PA</given-names></name></person-group><article-title>Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters</article-title><source>Proc Natl Acad Sci USA</source><volume>105</volume><fpage>12128</fpage><lpage>12133</lpage><year>2008</year><pub-id pub-id-type="doi">10.1073/pnas.0805374105</pub-id><pub-id pub-id-type="pmid">18713866</pub-id></element-citation></ref>
<ref id="b80-br-0-0-639"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindgren</surname><given-names>M</given-names></name><name><surname>Rosenthal-Aizman</surname><given-names>K</given-names></name><name><surname>Saar</surname><given-names>K</given-names></name><name><surname>Eir&#x00ED;ksd&#x00F3;ttir</surname><given-names>E</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Sassian</surname><given-names>M</given-names></name><name><surname>Ostlund</surname><given-names>P</given-names></name><name><surname>H&#x00E4;llbrink</surname><given-names>M</given-names></name><name><surname>Langel</surname><given-names>U</given-names></name></person-group><article-title>Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide</article-title><source>Biochem Pharmacol</source><volume>71</volume><fpage>416</fpage><lpage>425</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.bcp.2005.10.048</pub-id><pub-id pub-id-type="pmid">16376307</pub-id></element-citation></ref>
<ref id="b81-br-0-0-639"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanasty</surname><given-names>R</given-names></name><name><surname>Dorkin</surname><given-names>JR</given-names></name><name><surname>Vegas</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name></person-group><article-title>Delivery materials for siRNA therapeutics</article-title><source>Nat Mater</source><volume>12</volume><fpage>967</fpage><lpage>977</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/nmat3765</pub-id><pub-id pub-id-type="pmid">24150415</pub-id></element-citation></ref>
<ref id="b82-br-0-0-639"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muratovska</surname><given-names>A</given-names></name><name><surname>Eccles</surname><given-names>MR</given-names></name></person-group><article-title>Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells</article-title><source>FEBS Lett</source><volume>558</volume><fpage>63</fpage><lpage>68</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/S0014-5793(03)01505-9</pub-id><pub-id pub-id-type="pmid">14759517</pub-id></element-citation></ref>
<ref id="b83-br-0-0-639"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favaro</surname><given-names>MT</given-names></name><name><surname>de Toledo</surname><given-names>MA</given-names></name><name><surname>Alves</surname><given-names>RF</given-names></name><name><surname>Santos</surname><given-names>CA</given-names></name><name><surname>Beloti</surname><given-names>LL</given-names></name><name><surname>Janissen</surname><given-names>R</given-names></name><name><surname>de la Torre</surname><given-names>LG</given-names></name><name><surname>Souza</surname><given-names>AP</given-names></name><name><surname>Azzoni</surname><given-names>AR</given-names></name></person-group><article-title>Development of a non-viral gene delivery vector based on the dynein light chain Rp3 and the TAT peptide</article-title><source>J Biotechnol</source><volume>173</volume><fpage>10</fpage><lpage>18</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.jbiotec.2014.01.001</pub-id><pub-id pub-id-type="pmid">24417903</pub-id></element-citation></ref>
<ref id="b84-br-0-0-639"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>JX</given-names></name><name><surname>Sun</surname><given-names>YX</given-names></name><name><surname>Deng</surname><given-names>JZ</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>XZ</given-names></name><name><surname>Zhuo</surname><given-names>RX</given-names></name></person-group><article-title>Construction of cell penetrating peptide vectors with N-terminal stearylated nuclear localization signal for targeted delivery of DNA into the cell nuclei</article-title><source>J Control Release</source><volume>155</volume><fpage>26</fpage><lpage>33</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.12.009</pub-id><pub-id pub-id-type="pmid">21187118</pub-id></element-citation></ref>
<ref id="b85-br-0-0-639"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schott</surname><given-names>JW</given-names></name><name><surname>Galla</surname><given-names>M</given-names></name><name><surname>Godinho</surname><given-names>T</given-names></name><name><surname>Baum</surname><given-names>C</given-names></name><name><surname>Schambach</surname><given-names>A</given-names></name></person-group><article-title>Viral and non-viral approaches for transient delivery of mRNA and proteins</article-title><source>Curr Gene Ther</source><volume>11</volume><fpage>382</fpage><lpage>398</lpage><year>2011</year><pub-id pub-id-type="doi">10.2174/156652311797415872</pub-id><pub-id pub-id-type="pmid">21787295</pub-id></element-citation></ref>
<ref id="b86-br-0-0-639"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eto</surname><given-names>Y</given-names></name><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Asavatanabodee</surname><given-names>R</given-names></name><name><surname>Kida</surname><given-names>S</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Mukai</surname><given-names>Y</given-names></name><name><surname>Mizuguchi</surname><given-names>H</given-names></name><name><surname>Kawasaki</surname><given-names>K</given-names></name><name><surname>Okada</surname><given-names>N</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name></person-group><article-title>Transduction of adenovirus vectors modified with cell-penetrating peptides</article-title><source>Peptides</source><volume>30</volume><fpage>1548</fpage><lpage>1552</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.peptides.2009.05.017</pub-id><pub-id pub-id-type="pmid">19467282</pub-id></element-citation></ref>
<ref id="b87-br-0-0-639"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gratton</surname><given-names>JP</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Griffith</surname><given-names>JW</given-names></name><name><surname>Babbitt</surname><given-names>RW</given-names></name><name><surname>Scotland</surname><given-names>RS</given-names></name><name><surname>Hickey</surname><given-names>R</given-names></name><name><surname>Giordano</surname><given-names>FJ</given-names></name><name><surname>Sessa</surname><given-names>WC</given-names></name></person-group><article-title>Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo</article-title><source>Nat Med</source><volume>9</volume><fpage>357</fpage><lpage>362</lpage><year>2003</year><pub-id pub-id-type="doi">10.1038/nm835</pub-id><pub-id pub-id-type="pmid">12598894</pub-id></element-citation></ref>
<ref id="b88-br-0-0-639"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Ohnuki</surname><given-names>M</given-names></name><name><surname>Narita</surname><given-names>M</given-names></name><name><surname>Ichisaka</surname><given-names>T</given-names></name><name><surname>Tomoda</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group><article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title><source>Cell</source><volume>131</volume><fpage>861</fpage><lpage>872</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id><pub-id pub-id-type="pmid">18035408</pub-id></element-citation></ref>
<ref id="b89-br-0-0-639"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahimi</surname><given-names>B</given-names></name></person-group><article-title>Reprogramming barriers and enhancers: Strategies to enhance the efficiency and kinetics of induced pluripotency</article-title><source>Cell Regen (Lond)</source><volume>4</volume><fpage>10</fpage><year>2015</year><pub-id pub-id-type="doi">10.1186/s13619-015-0024-9</pub-id><pub-id pub-id-type="pmid">26566431</pub-id></element-citation></ref>
<ref id="b90-br-0-0-639"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>I</given-names></name><name><surname>Nagasaki</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Konishi</surname><given-names>S</given-names></name><name><surname>Korogi</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Muro</surname><given-names>S</given-names></name><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Funato</surname><given-names>M</given-names></name><etal/></person-group><article-title>Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells</article-title><source>Stem Cell Rep</source><volume>3</volume><fpage>394</fpage><lpage>403</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.stemcr.2014.07.005</pub-id></element-citation></ref>
<ref id="b91-br-0-0-639"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamao</surname><given-names>H</given-names></name><name><surname>Mandai</surname><given-names>M</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>N</given-names></name><name><surname>Suga</surname><given-names>A</given-names></name><name><surname>Sugita</surname><given-names>S</given-names></name><name><surname>Kiryu</surname><given-names>J</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name></person-group><article-title>Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application</article-title><source>Stem Cell Rep</source><volume>2</volume><fpage>205</fpage><lpage>218</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.stemcr.2013.12.007</pub-id></element-citation></ref>
<ref id="b92-br-0-0-639"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waehler</surname><given-names>R</given-names></name><name><surname>Russell</surname><given-names>SJ</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name></person-group><article-title>Engineering targeted viral vectors for gene therapy</article-title><source>Nat Rev Genet</source><volume>8</volume><fpage>573</fpage><lpage>587</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/nrg2141</pub-id><pub-id pub-id-type="pmid">17607305</pub-id></element-citation></ref>
<ref id="b93-br-0-0-639"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woltjen</surname><given-names>K</given-names></name><name><surname>Michael</surname><given-names>IP</given-names></name><name><surname>Mohseni</surname><given-names>P</given-names></name><name><surname>Desai</surname><given-names>R</given-names></name><name><surname>Mileikovsky</surname><given-names>M</given-names></name><name><surname>H&#x00E4;m&#x00E4;l&#x00E4;inen</surname><given-names>R</given-names></name><name><surname>Cowling</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Gertsenstein</surname><given-names>M</given-names></name><etal/></person-group><article-title>piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells</article-title><source>Nature</source><volume>458</volume><fpage>766</fpage><lpage>770</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/nature07863</pub-id><pub-id pub-id-type="pmid">19252478</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="tI-br-0-0-639" position="float">
<label>Table I.</label>
<caption><p>Cell-penetrating peptide classifications and sequences.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Study, year</th>
<th align="center" valign="bottom">Classification</th>
<th align="center" valign="bottom">Peptide</th>
<th align="center" valign="bottom">Sequences</th>
<th align="center" valign="bottom">Main trait</th>
<th align="center" valign="bottom">Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Green and Loewenstein, 1988</td>
<td align="left" valign="top">Cationic</td>
<td align="left" valign="top">Tat</td>
<td align="left" valign="top">GRKKRRQRRRPPQ</td>
<td align="left" valign="top">High positive charge</td>
<td align="right" valign="top">&#x00A0;&#x00A0;(<xref rid="b2-br-0-0-639" ref-type="bibr">2</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Frankel and Pabo, 1988</td>
<td/>
<td/>
<td/>
<td/>
<td align="right" valign="top">&#x00A0;&#x00A0;(<xref rid="b3-br-0-0-639" ref-type="bibr">3</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Joliot <italic>et al</italic>, 1991</td>
<td/>
<td align="left" valign="top">Antp</td>
<td align="left" valign="top">RQIKIWFQNRRMKWKK</td>
<td/>
<td align="right" valign="top">&#x00A0;&#x00A0;(<xref rid="b4-br-0-0-639" ref-type="bibr">4</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Ragin <italic>et al</italic>, 2002</td>
<td/>
<td align="left" valign="top">NLS</td>
<td align="left" valign="top">CGYGPKKKRKVGG</td>
<td/>
<td align="right" valign="top">(<xref rid="b15-br-0-0-639" ref-type="bibr">15</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Wender <italic>et al</italic>, 2000</td>
<td/>
<td align="left" valign="top">8-Arginine</td>
<td align="left" valign="top">RRRRRRRR</td>
<td/>
<td align="right" valign="top">(<xref rid="b11-br-0-0-639" ref-type="bibr">11</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Mai <italic>et al</italic>, 2002</td>
<td/>
<td align="left" valign="top">8-Lysine</td>
<td align="left" valign="top">KKKKKKKK</td>
<td/>
<td align="right" valign="top">(<xref rid="b12-br-0-0-639" ref-type="bibr">12</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Oehlke <italic>et al</italic>, 1998</td>
<td align="left" valign="top">Amphipathic</td>
<td align="left" valign="top">MPG</td>
<td align="left" valign="top">GLAFLGFLGAAGSTM</td>
<td align="left" valign="top">Chimeric peptides</td>
<td align="right" valign="top">(<xref rid="b16-br-0-0-639" ref-type="bibr">16</xref>)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left" valign="top">GAWSQPKKKRKV</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Deshayes <italic>et al</italic>, 2004</td>
<td/>
<td align="left" valign="top">pVEC</td>
<td align="left" valign="top">LLIILRRRIRKQAHAHSK</td>
<td/>
<td align="right" valign="top">(<xref rid="b17-br-0-0-639" ref-type="bibr">17</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Nan <italic>et al</italic>, 2011</td>
<td/>
<td align="left" valign="top">ARF (1&#x2013;22)</td>
<td align="left" valign="top">MVRRFLVTL</td>
<td/>
<td align="right" valign="top">(<xref rid="b18-br-0-0-639" ref-type="bibr">18</xref>)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left" valign="top">RIRRACGPPRVRV</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Johansson <italic>et al</italic>, 2008</td>
<td/>
<td align="left" valign="top">BPrPp (1&#x2013;28)</td>
<td align="left" valign="top">MVKSKIGSWILVLFV</td>
<td/>
<td align="right" valign="top">(<xref rid="b19-br-0-0-639" ref-type="bibr">19</xref>)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left" valign="top">SDVGLCKKRP</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Elliot and O&#x0027;Hare, 1997</td>
<td/>
<td align="left" valign="top">VP22</td>
<td align="left" valign="top">NAATATRGRSAASRPTQR</td>
<td/>
<td align="right" valign="top">&#x00A0;&#x00A0;(<xref rid="b5-br-0-0-639" ref-type="bibr">5</xref>)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left" valign="top">PRAPARSASRPRRPVQ</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Magzoub <italic>et al</italic>, 2006</td>
<td/>
<td align="left" valign="top">VT5</td>
<td align="left" valign="top">DPKGDPKGVTVT</td>
<td/>
<td align="right" valign="top">(<xref rid="b20-br-0-0-639" ref-type="bibr">20</xref>)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left" valign="top">VTVTVTGKGDPKPD</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Eguchi and Dowdy, 2009</td>
<td/>
<td/>
<td/>
<td/>
<td align="right" valign="top">(<xref rid="b21-br-0-0-639" ref-type="bibr">21</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Oehlke <italic>et al</italic>, 1998</td>
<td/>
<td align="left" valign="top">MAP</td>
<td align="left" valign="top">KLALKLALK</td>
<td/>
<td align="right" valign="top">(<xref rid="b16-br-0-0-639" ref-type="bibr">16</xref>)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left" valign="top">ALKAALKLA</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Pujals and Giralt, 2008</td>
<td align="left" valign="top">Hydrophobic</td>
<td align="left" valign="top">Transportan</td>
<td align="left" valign="top">GWTLNSAGYLLG</td>
<td align="left" valign="top">Contain only apolar residues; have a low net charge</td>
<td align="right" valign="top">(<xref rid="b23-br-0-0-639" ref-type="bibr">23</xref>)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td align="left" valign="top">KINLKALAALAKKIL</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Gao <italic>et al</italic>, 2011</td>
<td/>
<td align="left" valign="top">SG3</td>
<td align="left" valign="top">RLSGMNEVLSFRW</td>
<td/>
<td align="right" valign="top">(<xref rid="b28-br-0-0-639" ref-type="bibr">28</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Gao <italic>et al</italic>, 2002</td>
<td/>
<td align="left" valign="top">Pep-7</td>
<td align="left" valign="top">SDLWEMMMVSLACQY</td>
<td/>
<td align="right" valign="top">(<xref rid="b29-br-0-0-639" ref-type="bibr">29</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Nakayama <italic>et al</italic>, 2011</td>
<td/>
<td align="left" valign="top">FGF</td>
<td align="left" valign="top">PIEVCMYREP</td>
<td/>
<td align="right" valign="top">(<xref rid="b30-br-0-0-639" ref-type="bibr">30</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="tII-br-0-0-639" position="float">
<label>Table II.</label>
<caption><p>Cell-penetrating peptide uptake mechanisms.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Study, year</th>
<th align="center" valign="bottom">Pathway</th>
<th align="center" valign="bottom">Main trait</th>
<th align="center" valign="bottom">Examples</th>
<th align="center" valign="bottom">Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Vives <italic>et al</italic>, 1997</td>
<td align="left" valign="top">Direct penetration</td>
<td align="left" valign="top">Energy-independent</td>
<td align="left" valign="top">Tat peptide</td>
<td align="center" valign="top">(<xref rid="b36-br-0-0-639" ref-type="bibr">36</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Derossi <italic>et al</italic>, 1994</td>
<td align="left" valign="top">Direct penetration</td>
<td align="left" valign="top">Energy-independent</td>
<td align="left" valign="top">pAntp</td>
<td align="center" valign="top">(<xref rid="b37-br-0-0-639" ref-type="bibr">37</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Richard <italic>et al</italic>, 2003</td>
<td align="left" valign="top">Endocytosis</td>
<td align="left" valign="top">Energy-dependent</td>
<td align="left" valign="top">Polyarginine</td>
<td align="center" valign="top">(<xref rid="b42-br-0-0-639" ref-type="bibr">42</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Nan <italic>et al</italic>, 2011</td>
<td align="left" valign="top">Endocytosis</td>
<td align="left" valign="top">Energy-dependent</td>
<td align="left" valign="top">ARF (1&#x2013;22)</td>
<td align="center" valign="top">(<xref rid="b18-br-0-0-639" ref-type="bibr">18</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Kawamoto <italic>et al</italic>, 2011</td>
<td align="left" valign="top">Via the formation of a transitory membrane structure</td>
<td align="left" valign="top">Formation of the inverted micelles</td>
<td align="left" valign="top">Arginine-rich peptide</td>
<td align="center" valign="top">(<xref rid="b47-br-0-0-639" ref-type="bibr">47</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="tIII-br-0-0-639" position="float">
<label>Table III.</label>
<caption><p>Cell-penetrating peptide applications.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Study, year</th>
<th align="center" valign="bottom">Application</th>
<th align="center" valign="bottom">Examples</th>
<th align="center" valign="bottom">Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Ruan <italic>et al</italic>, 2007</td>
<td align="left" valign="top">Imaging</td>
<td align="left" valign="top">Tat-QDs</td>
<td align="center" valign="top">(<xref rid="b55-br-0-0-639" ref-type="bibr">55</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Lei <italic>et al</italic>, 2008</td>
<td/>
<td/>
<td align="center" valign="top">(<xref rid="b56-br-0-0-639" ref-type="bibr">56</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Prantner <italic>et al</italic>, 2003</td>
<td/>
<td align="left" valign="top">Gd-DOTA-D-Tat</td>
<td align="center" valign="top">(<xref rid="b57-br-0-0-639" ref-type="bibr">57</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Polyakov <italic>et al</italic>, 2000</td>
<td/>
<td align="left" valign="top">Tat-(99m)Tc</td>
<td align="center" valign="top">(<xref rid="b58-br-0-0-639" ref-type="bibr">58</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Deshayes <italic>et al</italic>, 2010</td>
<td align="left" valign="top">Anti-inflammation</td>
<td align="left" valign="top">CPP-PNA</td>
<td align="center" valign="top">(<xref rid="b63-br-0-0-639" ref-type="bibr">63</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Tan <italic>et al</italic>, 2005</td>
<td/>
<td/>
<td align="center" valign="top">(<xref rid="b64-br-0-0-639" ref-type="bibr">64</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Tilley <italic>et al</italic>, 2007</td>
<td/>
<td align="left" valign="top">CPP-PMO</td>
<td align="center" valign="top">(<xref rid="b65-br-0-0-639" ref-type="bibr">65</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Dav&#x00E9; <italic>et al</italic>, 2007</td>
<td/>
<td align="left" valign="top">CPP-NBD</td>
<td align="center" valign="top">(<xref rid="b71-br-0-0-639" ref-type="bibr">71</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Peterson <italic>et al</italic>, 2011</td>
<td/>
<td align="left" valign="top">Antp-NBD</td>
<td align="center" valign="top">(<xref rid="b72-br-0-0-639" ref-type="bibr">72</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Koshkaryev <italic>et al</italic>, 2013</td>
<td align="left" valign="top">Tumor therapy</td>
<td align="left" valign="top">R8-DOPE-BLM</td>
<td align="center" valign="top">(<xref rid="b76-br-0-0-639" ref-type="bibr">76</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Walker <italic>et al</italic>, 2012</td>
<td/>
<td align="left" valign="top">DOXO-ELP-CPP</td>
<td align="center" valign="top">(<xref rid="b77-br-0-0-639" ref-type="bibr">77</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Aroui <italic>et al</italic>, 2010</td>
<td/>
<td align="left" valign="top">Dox</td>
<td align="center" valign="top">(<xref rid="b78-br-0-0-639" ref-type="bibr">78</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Dubikovskaya <italic>et al</italic>, 2008</td>
<td/>
<td align="left" valign="top">Taxol</td>
<td align="center" valign="top">(<xref rid="b79-br-0-0-639" ref-type="bibr">79</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Lindgren <italic>et al</italic>, 2006</td>
<td/>
<td align="left" valign="top">Methotrexate</td>
<td align="center" valign="top">(<xref rid="b80-br-0-0-639" ref-type="bibr">80</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Eguchi and Dowdy, 2009</td>
<td align="left" valign="top">Nucleic acid and Protein delivery</td>
<td align="left" valign="top">CPP-siRNA</td>
<td align="center" valign="top">(<xref rid="b21-br-0-0-639" ref-type="bibr">21</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Muratovska and Eccles, 2004</td>
<td/>
<td/>
<td align="center" valign="top">(<xref rid="b82-br-0-0-639" ref-type="bibr">82</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Favaro <italic>et al</italic>, 2014</td>
<td/>
<td align="left" valign="top">T-Rp3</td>
<td align="center" valign="top">(<xref rid="b83-br-0-0-639" ref-type="bibr">83</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Eto <italic>et al</italic>, 2009</td>
<td align="left" valign="top">Viral delivery</td>
<td align="left" valign="top">CPP-Adv</td>
<td align="center" valign="top">(<xref rid="b86-br-0-0-639" ref-type="bibr">86</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
